Teleflex Incorporated

NYSE:TFX Stock Report

Market Cap: US$9.0b

Teleflex Valuation

Is TFX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TFX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TFX ($187.43) is trading below our estimate of fair value ($460.84)

Significantly Below Fair Value: TFX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TFX?

Key metric: As TFX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TFX. This is calculated by dividing TFX's market cap by their current earnings.
What is TFX's PE Ratio?
PE Ratio36.6x
EarningsUS$238.01m
Market CapUS$8.97b

Price to Earnings Ratio vs Peers

How does TFX's PE Ratio compare to its peers?

The above table shows the PE ratio for TFX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average77.1x
MASI Masimo
112.4x29.6%US$8.8b
BAX Baxter International
137.7x39.8%US$16.6b
ZBH Zimmer Biomet Holdings
20.1x8.1%US$22.1b
ITGR Integer Holdings
38.4x20.8%US$4.5b
TFX Teleflex
36.6x22.8%US$9.0b

Price-To-Earnings vs Peers: TFX is good value based on its Price-To-Earnings Ratio (36.6x) compared to the peer average (77.1x).

Price to Earnings Ratio vs Industry

How does TFX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.8xn/aUS$13.37m
PAVM PAVmed
0.7x-77.8%US$10.61m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
TFX 36.6xIndustry Avg. 36.1xNo. of Companies10PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TFX is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the US Medical Equipment industry average (35.4x).

Price to Earnings Ratio vs Fair Ratio

What is TFX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TFX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36.6x
Fair PE Ratio35.5x

Price-To-Earnings vs Fair Ratio: TFX is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the estimated Fair Price-To-Earnings Ratio (35.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TFX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$187.43
US$245.01
+30.7%
8.7%US$285.00US$214.00n/a13
Nov ’25US$211.21
US$245.01
+16.0%
8.7%US$285.00US$214.00n/a13
Oct ’25US$245.13
US$258.65
+5.5%
6.3%US$285.00US$225.00n/a13
Sep ’25US$245.17
US$260.89
+6.4%
6.7%US$290.00US$225.00n/a14
Aug ’25US$235.95
US$253.88
+7.6%
7.7%US$285.00US$220.00n/a13
Jul ’25US$211.44
US$246.60
+16.6%
9.5%US$285.00US$210.00n/a14
Jun ’25US$209.07
US$245.23
+17.3%
10.9%US$285.00US$205.00n/a13
May ’25US$211.54
US$261.53
+23.6%
6.0%US$285.00US$225.00n/a14
Apr ’25US$222.88
US$263.31
+18.1%
5.5%US$285.00US$225.00n/a14
Mar ’25US$223.00
US$261.54
+17.3%
6.7%US$285.00US$211.00n/a14
Feb ’25US$247.65
US$263.46
+6.4%
7.4%US$285.00US$211.00n/a14
Jan ’25US$249.34
US$251.75
+1.0%
9.1%US$285.00US$211.00n/a14
Dec ’24US$227.67
US$239.67
+5.3%
8.9%US$285.00US$211.00n/a14
Nov ’24US$187.51
US$246.67
+31.6%
12.6%US$315.00US$210.00US$211.2114
Oct ’24US$196.41
US$259.31
+32.0%
12.2%US$315.00US$210.00US$245.1314
Sep ’24US$213.55
US$264.06
+23.7%
10.4%US$315.00US$211.00US$245.1714
Aug ’24US$249.28
US$268.14
+7.6%
10.9%US$330.00US$211.00US$235.9514
Jul ’24US$242.03
US$267.42
+10.5%
10.6%US$330.00US$211.00US$211.4414
Jun ’24US$233.77
US$271.53
+16.2%
10.6%US$330.00US$211.00US$209.0715
May ’24US$274.11
US$266.93
-2.6%
10.8%US$330.00US$211.00US$211.5414
Apr ’24US$253.31
US$260.07
+2.7%
11.1%US$330.00US$211.00US$222.8815
Mar ’24US$233.66
US$260.07
+11.3%
11.1%US$330.00US$211.00US$223.0015
Feb ’24US$250.18
US$258.00
+3.1%
12.8%US$330.00US$211.00US$247.6515
Jan ’24US$249.63
US$254.40
+1.9%
14.0%US$330.00US$211.00US$249.3415
Dec ’23US$244.80
US$247.93
+1.3%
14.8%US$330.00US$211.00US$227.6714
Nov ’23US$219.24
US$247.93
+13.1%
14.8%US$330.00US$211.00US$187.5114

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%